Exosomal Non-coding RNAs as Potential Biomarkers for Alzheimer's Disease: Advances and Perspectives in Translational Research
Authors:
- Simoneide Souza Titze-De-AlmeidaSTSimoneide Souza Titze-De-Almeida
- Clara Luna MarinaCMClara Luna Marina
- Milena Vieira RamosMRMilena Vieira Ramos
- Letícia Dias dos Santos SilvaLSLetícia Dias dos Santos Silva
- Pedro Renato de Paula BrandãoPedro Renato de Paula Brandão
- Diógenes Diego de Carvalho BispoDBDiógenes Diego de Carvalho Bispo
- Felipe Von GlehnFGFelipe Von Glehn
- Ricardo Titze-De-AlmeidaRTRicardo Titze-De-Almeida
Preprint
- 15 April 2025
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory loss and cognitive decline, which significantly impacts patients' quality of life and imposes substantial emotional, practical, and economic burdens on their families. As the most common cause of senile dementia, AD currently affects approximately 50 million people worldwide, with projections indicating a threefold increase by 2050 due to rising life expectancy and an aging global population. Diagnosis of AD remains challenging. Neuroimaging techniques reveal atrophy in critical brain regions, particularly in the cortex, hippocampus, and limbic system, which are essential substrates for memory, personality changes, and other cognitive functions. The hallmark molecular changes associated with AD include the accumulation of β-amyloid plaques and the formation of tau protein tangles. Several underlying mechanisms contribute to neuron loss, such as oxidative stress, neuroinflammation, microbial dysbiosis and insulin resistance. In this context, exosomes − small extracellular vesicles that facilitate cell communication − transport proteins, DNA, mRNA, and non-coding RNA (ncRNA), all of which play a significant role in the neurobiology of AD. Furthermore, emerging research indicates that exosomal ncRNAs may serve as promising biomarkers for AD, offering the possibility of improved diagnostic precision. This review explores the potential of exossomal ncRNAs as non-invasive biomarkers for AD, focusing on recent advances and future directions in translational studies.Keywords
All Related Versions
This publication has 105 references indexed in Scilit:
- Extracellular Vesicles of Alzheimer’s Disease Patients as a Biomarker for Disease ProgressionMolecular Neurobiology, 2020
- Association of Extracellular Vesicle Biomarkers With Alzheimer Disease in the Baltimore Longitudinal Study of AgingJAMA Neurology, 2019
- Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Attributable risk of Alzheimer's dementia attributed to age‐related neuropathologiesAnnals of Neurology, 2018
- High complement levels in astrocyte‐derived exosomes of Alzheimer diseaseAnnals of Neurology, 2018
- The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical MarketPharmaceutical Research, 2017
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approachActa Neuropathologica, 2011
- Preclinical Evidence of Alzheimer ChangesArchives of Neurology, 2009
- Oligodendrocytes secrete exosomes containing major myelin and stress‐protective proteins: Trophic support for axons?Proteomics – Clinical Applications, 2007
- Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐BAnnals of Neurology, 2004